Phaseline

Targets › FASN

FASN (Fatty acid synthase): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Dec 2026.

Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. This multifunctional protein contains 7 catalytic activities and a site for the binding of the prosthetic group 4'-phosphopantetheine of the acyl carrier protein ([ACP]) domain..; FUNCTION: (Microbial infection) Fatty acid…. (UniProt, P49327)

Open in Phaseline: the race on FASN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
David E GerberTVB-2640
Fatty acid synthase (FASN) inhibitor
FASNPhase 2KRAS Gene MutationDec 2026
Weill Medical College of Cornell UniversityTVB-2640
Fatty acid synthase (FASN) inhibitor
FASNPhase 1Prostatic Neoplasms, Castration-ResistantJan 2028

Conditions

Prostatic Neoplasms, Castration-Resistant (1) KRAS Gene Mutation (1)

Modalities

small molecule (2)

Companies

Weill Medical College of Cornell University (1) David E Gerber (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.